术后化疗对早期肺大细胞神经内分泌肿瘤患者生存期的影响

韩轲; 范力文; 赵珩

doi:10.3969/j.issn.1000-8179.2017.04.286

术后化疗对早期肺大细胞神经内分泌肿瘤患者生存期的影响

Role of postoperative chemotherapy in patients with early-stage pulmonary large-cell neuroendocrine carcinoma after resection

摘要

摘要:
目的探讨术后化疗对早期肺大细胞神经内分泌肿瘤（large cell neuroendocrine carcinoma，LCNEC）患者生存期的影响。
方法回顾性分析2008年1月至2014年12月在上海交通大学附属胸科医院50例行肺癌根治性切除及系统性淋巴结清扫LCNEC患者的临床资料，根据术后是否接受化疗将50例患者分为化疗组（n=32）和非化疗组（n=18）。随访其生存状况。
结果化疗组和非化疗组中位生存时间分别为48个月和29个月，5年总生存率分别为72.5%和35.6%。单因素及多因素Cox分析均表明：术后辅助化疗为LCNEC患者OS的预后影响因素（P=0.005；HR=0.281，P=0.008）。
结论术后化疗可提高早期LCNEC术后患者的远期生存率。

Abstract:
Objective To investigate the efficacy of postoperative chemotherapy in patients with early-stage pulmonary large cell neuroendocrine carcinoma (LCNEC) after resection.
Methods A cohort of 50 patients who underwent resection and systematic nodal dissection for LCNEC between January 2008 and December 2014 in our institution was retrospectively reviewed. The patients were divided into adjuvant chemotherapy group (32 cases) and non-chemotherapy group (18 cases). Follow-up information was investigated.
Results The median survival and the 5-year survival rate were 48 months and 72.5% for the adjuvant chemotherapy group whereas 29 months and 35.6% for the non-adjuvant chemotherapy group, respectively. Univariate and multivariate analyses using Cox's proportional hazard models showed that postoperative chemotherapy was a signifi cant prognostic factor for OS (P=0.005; hazard ratio= 0.281, P=0.008, respectively).
Conclusion Postoperative chemotherapy is beneficial to patients with early-stage pulmonary LCNEC after complete resection.

HTML全文

参考文献(16)

施引文献

资源附件(0)